© 2024 Public Radio Tulsa
800 South Tucker Drive
Tulsa, OK 74104
(918) 631-2577

A listener-supported service of The University of Tulsa
classical 88.7 | public radio 89.5
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Impotence Drug Approved To Treat Enlarged Prostate Symptoms

<p>The FDA says the same pill can be used to treat BPH and erectile dysfunction.</p>
Eli Lilly

The FDA says the same pill can be used to treat BPH and erectile dysfunction.

In other men's health news today, the Food and Drug Administration approved the use of Cialis as a once-a-day treatment for symptoms caused by an enlarged prostate.

That makes Cialis, a popular pill for impotence, the first drug of its kind to also be okayed for benign prostatic hyperplasia. Those symptoms include difficulty in starting urination and frequent trips to the bathroom in the middle of the night.

The FDA says it's the ninth medicine to be approved to help men with drug becomes the ninth approved by FDA to help men with BPH.

A month's supply of 5 milligram Cialis tablets, the dose approved for BPH, costs $134 at drugstore.com. A month's supply of generic terazosin (once sold as Hytrin) for BPH costs $14.00.

In two clinical studies, daily Cialis treatment lowered the score on a standardized test of prostate symptoms by almost 5 points, or around 25 percent from the starting point. In both studies the result was about twice as good as seen for men taking placebo. Another study showed improvements for erections and BPH.

Common side effects include headache, stomach upset, back pain and muscle aches. Eli Lilly, maker of the pill, doesn't know exactly how the drug works to relieve symptoms of BPH.

I wondered what's next for Cialis? A switch to over-the-counter status, perhaps? A Lilly spokeswoman said there's no plan for anything like that. And a generic, if you're curious is years away. Patents will protect the drug in the U.S. until 2017.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Scott Hensley
Scott Hensley edits stories about health, biomedical research and pharmaceuticals for NPR's Science desk. During the COVID-19 pandemic, he has led the desk's reporting on the development of vaccines against the coronavirus.